INTRODUCTION {#S1}
============

Protein expression in cells is controlled not only by regulation of transcription, splicing, and export of coding mRNAs but also through the presence or absence of regulatory sequences located in the 5′ and 3′ UTRs of mRNA. In particular, 3′ UTRs have been shown to be the primary site of microRNA (miRNA) association and function ([@R3]; [@R25]; [@R34]) as well as containing binding sites for proteins that regulate translation, mRNA stability, and subcellular localization of mRNA ([@R25]; [@R34]). The interaction of such regulatory factors with *cis*-acting elements in the 3′ UTR controls the level of protein expression, as well as protein phosphorylation, localization, and activity, by determining where and when a protein is translated in the cell ([@R4]; [@R5]; [@R19]). Therefore, the identity of the 3′ UTR plays a critical role in determining the ultimate expression and function of the upstream open reading frame.

Importantly, the 3′ UTR of a given gene is not static but rather can vary in a tissue- and condition-specific manner through at least two mechanisms: alternative splicing and alternative polyadenylation. Alternative splicing within 3′ UTRs, including retention of introns, has been reported in 6%--16% of human protein-coding genes, although this may be an underestimate ([@R6]). Splicing in 3′ UTRs is generally thought to target messages for nonsense-mediated decay and has not been broadly studied ([@R6]; [@R17]). In contrast, much attention has recently been focused on alternative polyadenylation, which occurs over half of human protein-coding genes ([@R11]; [@R14]; [@R35]; [@R34]) and can alter protein expression or function by altering the presence or absence of binding sites within 3′ UTRs for miRNAs and regulatory proteins ([@R25]; [@R28]; [@R34]).

Polyadenylation is the addition of \~200 adenosine bases to the exposed 3′ hydroxyl group generated by co-transcriptional cleavage of a nascent transcript. Alternative polyadenylation (APA) refers to cases in which cleavage, and subsequent polyadenylation, occurs at different positions on a transcript in a condition or cell type-specific manner ([@R34]). Such APA results in truncation of the open reading frame if cleavage occurs prior to the final coding exons. On the other hand, when both or all of the cleavage events are downstream of the stop codon, APA results in 3′ UTRs of distinct lengths.

Cleavage and polyadenylation is mediated by a large multi-component complex consisting of the core CPSF (cleavage and polyadenylation stimulation factor) subcomplex as well as additional enhancer subcomplexes CFI (cleavage factor I), CFII (cleavage factor II), and CstF (cleavage stimulatory factor) ([@R31]). These four subcomplexes (also known as the cleavage and polyadenylation factors \[CPAFs\]) associate in a cooperative manner with genomically encoded sequence motifs comprising a hexameric AAUAAA (also known as the polyadenylation sequence \[PAS\]) and upstream and downstream U/G-rich sequences. The AAUAAA hexamer is the primary binding site for the CPSF complex and directs the location of cleavage, whereas CFI binds to an upstream UGUA and CstF associates with a U/G-rich element downstream of the core hexamer ([@R31]). Importantly, because each of these interactions is relatively weak, the cooperative assembly of CPSF with CFI and CstF helps ensure efficiency of binding and accurate positioning of the overall complex ([@R34]). Consistently, several groups have shown that increased expression or recruitment of CFI and CstF can direct the catalytic activity of CPSF to regions of the transcript that lack a perfect AAUAAA element, thereby enhancing polyadenylation at an otherwise suboptimal ("weak") site ([@R7]; [@R22]; [@R32]; [@R34]; [@R42]). Additional RNA-binding proteins (RBPs) can also promote or hinder the association of CPAFs with particular sites through protein-protein interactions or steric hindrance, respectively ([@R34]). Such regulation of the binding of CPAFs to low- and high-affinity sites, through changes in the expression of individual CPAFs or regulatory RBPs, is thought to drive the majority of APA ([@R34]).

APA has been shown to be broadly regulated in a cell type-and signal-responsive manner, including in response to cellular proliferation. For example, in one study, approximately 5% of genes surveyed undergo APA during antigen-induced proliferative growth of human CD4+ T cells ([@R28]), a required step in a proper immune response. However, only a very few proteins have thus far been identified as essential for regulating the widespread and coordinated APA that has been observed in T cells or other examples of signal-induced APA. We have previously shown that expression of the RBP CELF2 is induced upon stimulation of the Jurkat T cell line and binds broadly to exons, introns, and 3′ UTRs within these cells ([@R2]; [@R20]). CELF2 is a member of the CUG-BP, Elav-like family (CELF) of binding proteins. It binds preferentially to single-stranded UG and CUG-rich RNA elements and has been widely studied as a regulator of splicing in heart and skeletal muscle, neurons, and T cells ([@R9]; [@R13]; [@R16]). We have previously shown that increased CELF2 protein activity in response to T cell signaling drives alternative splicing of more than 100 genes ([@R13]; [@R21]). However, the functional consequence of the pervasive binding of CELF2 to 3′ UTRs has not been explored.

Here we show that CELF2 regulates both 3′ UTR intron retention and APA on its own transcript as well as many others. The regulation of intron retention involves competition between CELF2 and the 65 kDa subunit of the U2-auxiliary factor (U2AF65) for binding to the polypyrimidine tract, consistent with previous studies demonstrating steric hindrance of 3′ splice site use by CELF2 ([@R10]). In contrast, a widespread role for CELF2 in APA has not previously been described. We show here that CELF2 mediates APA by competing with the CFI and CstF complexes for substrate binding. Increased expression of CELF2 induced upon stimulation of Jurkat T cells results in decreased use of a weak (non-canonical) PAS site in the CELF2 3′ UTR, while mutation of the CFI and CstF binding sites around this weak PAS mimics stimulation and reduces the impact of CELF2 expression. Importantly, transcriptome-wide binding of CELF2 in the 3′ UTR markedly overlaps the binding sites for CFI and CstF. Moreover, we show that knockdown of CELF2 in Jurkat cells abrogates the stimulation-induced APA of many mRNAs, resulting in regulation of mRNA and protein expression. In particular, we demonstrate that CELF2-regulated APA drives CELF2-dependent repression of RBFox2 expression, which we have previously shown to shape splicing programs in many cell types ([@R13]). Together, our data demonstrate a previously unrecognized activity of CELF2 in shaping 3′ UTR identity and suggest that regulation of CELF2 expression may underlie much of the APA that has been previously observed in proliferating cells.

RESULTS {#S2}
=======

CELF2 Binds Its Own 3′ UTR and Induces Intron Retention and APA {#S3}
---------------------------------------------------------------

Our previous transcriptome-wide mapping of CELF2 binding to RNA in the Jurkat T cells revealed the surprising discovery that CELF2 binding is enriched in 3′ UTRs ([@R2]) ([Figure 1A](#F1){ref-type="fig"}). Although CELF2 has been described primarily as a regulator of splicing ([@R9]; [@R16]), the extensive 3′ UTR binding suggests further undetermined roles of CELF2 in RNA biogenesis. To begin to investigate the functional impact of CELF2 3′ UTR binding, we looked for 3′ UTRs that exhibited strong binding and potential regulation in the Jurkat T cells.

Interestingly, one of the 3′ UTRs in which we observe extensive binding of CELF2 protein by crosslinking immunoprecipitation sequencing (CLIP-seq) is the 3′ UTR of the CELF2 mRNA itself ([Figure 1B](#F1){ref-type="fig"}). Moreover, we have previously shown that both the retention of an intron and use of competing APA sites (PAS2 versus PAS3) is altered in the CELF2 3′ UTR upon stimulation of Jurkat cells with the phorbol ester PMA ([@R21]) ([Figure 1B](#F1){ref-type="fig"}). Importantly, PMA stimulation of Jurkat cells also results in a significant increase in CELF2 protein expression through an increase in both transcription and mRNA stability ([@R20], [@R21]). Analysis of protein expression, 3′ UTR intron retention (IR), and APA across a time course of stimulation revealed that the predominant spike in CELF2 protein occurs in the first 8--12 h of PMA stimulation, whereas significant changes in IR or APA of the CELF2 3′ UTR are not observed until 12--16 hours after PMA treatment ([Figures 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}). The fact that increased CELF2 protein precedes a change in IR or APA suggests a role of CELF2 protein in autoregulation of its own 3′ UTR. To more directly test the causality of CELF2 protein expression in 3′ UTR regulation, we used a doxycycline-inducible promoter driving a CELF2 cDNA expression construct. Strikingly, we find that doxycycline induction of CELF2 protein is sufficient to induce both IR and APA in the endogenous CELF2 3′ UTR, strongly suggesting that CELF2 protein directly regulates IR and APA in the CELF2 3′ UTR ([Figures 1E](#F1){ref-type="fig"} and [S1](#SD2){ref-type="supplementary-material"}).

CELF2 Is Necessary and Sufficient for IR by Inhibiting U2AF65 Binding {#S4}
---------------------------------------------------------------------

We first sought to further investigate the regulation of IR by CELF2, as this is consistent with known activities of CELF2. We generated a CELF2-knockout (KO) Jurkat cell line by mutation of exon 5 by CRISPR (see [STAR Methods](#S9){ref-type="sec"}) to introduce a stop codon, resulting in cells that lack any detec\] CELF2 protein but retain near normal mRNA expression ([Figure 2A](#F2){ref-type="fig"}). In this cell line we observe no increased CELF2 3′ UTR IR upon treatment with PMA, demonstrating that CELF2 protein is necessary for PMA-induced retention of the 3′ UTR intron ([Figure 2A](#F2){ref-type="fig"}). We observe a similar loss of 3′ UTR IR in Jurkat cells that are depleted of CELF2 by short hairpin RNA (shRNA) ([Figure S2](#SD1){ref-type="supplementary-material"}), although in these cells there is less CELF2 mRNA as well as less protein, thus hindering robust conclusions. To determine, conversely, if CELF2 is sufficient for IR in the absence of other T cell factors, we used HeLa cells that naturally lack any detectable CELF2 protein ([Figure 2B](#F2){ref-type="fig"}). Consistent with a causative role for CELF2 in IR, we detect no IR in RNA from a CELF2 3′ UTR intron reporter construct transfected into HeLa cells either on its own or co-transfected with cDNA encoding GFP, while cotransfection with CELF2 cDNA induces almost complete IR ([Figure 2B](#F2){ref-type="fig"}). Together, these data demonstrate that CELF2 protein is necessary and sufficient to induce retention of its own 3′ UTR intron.

Previous studies have shown that CELF2 represses 3′ splice site use by competing with U2AF65 ([@R10]). Close examination of the CLIP-seq data reveals that CELF2 CLIP peaks exactly overlap the 3′ polypyrimidine track of the 3′ UTR intron ([Figure 2C](#F2){ref-type="fig"}), which is the sequence to which U2AF65 binds to promote splicing ([@R1]). To ask whether CELF2 competes with U2AF65 for binding to the 3′ UTR intron, we carried out a UV crosslinking experiment using a radiolabeled RNA corresponding to 120 nt around the 3′ splice site of the 3′ UTR intron and nuclear extract from unstimulated and PMA-stimulated Jurkat cells ([Figure 2D](#F2){ref-type="fig"}). Consistent with the CLIP data, we find that both U2AF65 and CELF2 crosslink to the 3′ UTR intron in extract from unstimulated cells. By comparison, in extracts from stimulated cells, CELF2 crosslinking increases while U2AF65 crosslinking decreases ([Figure 2D](#F2){ref-type="fig"}). We conclude that the reduction in U2AF65 crosslinking is a direct result of increased CELF2 expression, as we observe a similar loss of U2AF65 signal when we add recombinant CELF2 protein to extract from unstimulated cells ([Figure 2E](#F2){ref-type="fig"}). Although in many instances competition between CELF2 and U2AF65 lead to exon skipping, repression of the 3′ splice site of a terminal intron is predicted to result in IR, as no alternative 3′ splice site is available (see [Discussion](#S8){ref-type="sec"}). Interestingly, in our previously published RNA sequencing (RNA-seq) data from wild-type and CELF2-depleted JSL1 cells ([@R13]), we find several instances of CELF2-dependent IR events in 3′ UTRs ([Table S1](#SD2){ref-type="supplementary-material"}; [Figure S2](#SD1){ref-type="supplementary-material"}). Although IR is not a focus of the present study, these data further highlight that the previously described role of CELF2 in 3′ splice site regulation can result in IR as well as exon skipping.

CELF2 Is Necessary and Sufficient for the Switch to PAS3 by Inhibiting Enhancer Elements Required for PAS2 {#S5}
----------------------------------------------------------------------------------------------------------

In contrast to its well-documented activity as a splicing regulator, CELF2 has not previously been shown to control cleavage and polyadenylation. To determine if, in addition to IR, CELF2 is necessary and sufficient to directly regulate APA of its 3′ UTR, we again used the KO, knockdown, and HeLa systems described above ([Figure 2](#F2){ref-type="fig"}). As we observed for IR, we find that the PMA-induced switch from PAS2 to PAS3 is abolished in the CELF2-KO and CELF2-knockdown Jurkat cells ([Figure 3A](#F3){ref-type="fig"}; [Figure S3](#SD1){ref-type="supplementary-material"}). Moreover, PAS3 is only used in HeLa cells upon co-transfection with CELF2 ([Figure 3B](#F3){ref-type="fig"}). Importantly, the use of PAS3 is not dependent on the IR activity of CELF2, as the CELF2-dependent use of PAS3 is equivalent in 3′ UTR PAS reporters that contain or lack the intron ([Figure 3B](#F3){ref-type="fig"}, +Intron versus−Intron). Therefore, we conclude that CELF2 directly activates an APA switch from PAS2 to PAS3.

To begin to understand how CELF2 may regulate APA, we analyzed the sequence features around PAS2 and PAS3. PAS3 has a canonical AAUAAA hexamer, whereas PAS2 has a divergent AUUAAA motif ([Figure 3C](#F3){ref-type="fig"}). The AUUAAA motif is known to recruit the CPSF complex less efficiently than the canonical sequence ([@R30]). However, we also note the presence of two UGUA enhancer elements 40--50 nt upstream of the PAS2 hexamer ([Figure 3C](#F3){ref-type="fig"}, box), as well as an extended U/G-rich enhancer element downstream ([Figure 3C](#F3){ref-type="fig"}, underline). The upstream enhancer (UE) UGUA is the binding site for CFIm25, the RNA-binding subunit of the CFI complex ([@R40]), while the downstream enhancer (DE) is bound by CstF64, the RNA-binding subunit of CstF. Both CFI and CstF facilitate recruitment of the CPSF complex through protein-protein interactions ([@R31]). Notably, both the UE and DE sequences closely mirror the U/G-rich binding preference of CELF2. We also observe that the PAS2-associated UGUA motifs and U/G-rich enhancer fall directly within CELF2 CLIP peaks ([Figure 3C](#F3){ref-type="fig"}). Therefore, we hypothesized that CELF2 may compete with CFIm25 or CstF64 for binding upstream or downstream of PAS2, respectively, thus decreasing the efficiency of PAS2 recognition to favor PAS3.

To directly test if CELF2 inhibits the binding of CFIm25 and/or CstF64 around PAS2, we carried out UV crosslinking using recombinant proteins and an RNA corresponding to PAS2 and approximately 85 nt of upstream and downstream sequence (see [STAR Methods](#S9){ref-type="sec"}). Consistent with our identification of binding sites for CELF2, CFim25 and CstF64 within this region of the CELF2 3′ UTR, we readily observe crosslinking of all three individual proteins to the RNA ([Figures 4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"}). Moreover, when CstF64 and CFIm25 are co-incubated with RNA, crosslinking of both of these proteins is observed ([Figure S4](#SD1){ref-type="supplementary-material"}). By contrast, addition of CELF2 results in reduced binding of CFIm25 and CstF64, in a dose-dependent manner, with a concomitant increase in binding of CELF2. This competition in binding is observed whether CFIm25 and CstF64 are alone or in combination with one another ([Figures 4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"}; [Figure S4A](#SD1){ref-type="supplementary-material"}). As a control, no competition in observed between CFIm25/CstF64 and hnRNP L or hnRNP K ([Figures 4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"}; [Figure S4B](#SD1){ref-type="supplementary-material"}) despite the fact that these proteins have been observed to bind to 3′ UTRs and C-rich elements, respectively (Figure S4). We also note that CELF2 competitively inhibits the binding of CFIm25 and CstF64 even when these proteins are present in molar excess, suggesting that CELF2 binds to this RNA with higher affinity than either CFIm25 or CstF64.

To provide further evidence of competition between CELF2 and CFIm25/CstF64 in cells, we also carried out mutagenesis of the PAS reporter construct used in [Figure 3B](#F3){ref-type="fig"}. Specifically we engineered mutations that disrupt binding of CFIm25, CstF64, and CELF2 around PAS2 and tested the impact of these mutations on use of PAS2 and PAS3 ([Figure 4C](#F4){ref-type="fig"}). Consistent with the prediction that use of PAS2 requires cooperative enhancing activity from CFI and CstF, mutation of either the CFIm25 (mUE) or CstF64 (mDE) binding site markedly reduced PAS2 use in favor of PAS3 in the absence of CELF2 ([Figure 4C](#F4){ref-type="fig"}). In both cases, CELF2 expression still resulted in a further increase in PAS3, presumably because of competition of CELF2 with the non-mutated element. However, mutation of both the UE and DE (mU/D) surrounding PAS2 is sufficient to flip APA fully to PAS3 and abrogate any impact of CELF2 addition ([Figure 4C](#F4){ref-type="fig"}). A similar, though less striking, result is also observed in constructs in which mutations are made that disrupt CFIm25 and CstF64 binding but maintain CELF2 binding (mU/D-C2; [Figure S4](#SD1){ref-type="supplementary-material"}). We can also rule out the alternative possibility that CELF2 also directly enhances PAS3, given that we observe a similar CELF2-induced reduction in PAS2 when PAS3 is replaced by the heterologous, unregulated PAS site from the reporter vector ([Figure 4C](#F4){ref-type="fig"}, swPAS3; see [Figure S4](#SD1){ref-type="supplementary-material"} for quantification). Moreover, improving the strength of PAS2 by inserting a consensus AAUAAA motif also increased the relative use of PAS2 over PAS3 in both the absence and presence of CELF2 ([Figure 4C](#F4){ref-type="fig"}). Thus, from both the biochemical and cellular data, we conclude that the primary mechanism by which CELF2 causes a switch from PAS2 to PAS3 is by inhibiting the use of PAS2 through competing with factors such as CFIm25 and CstF64 for binding to the required enhancer elements. This model is further consistent with the lack of CELF2 binding downstream of PAS3 and the fact that in the absence of CELF2 protein, PAS2 is used constitutively.

CELF2 Binding Overlaps Extensively with APA Enhancer Activities Transcriptome-wide {#S6}
----------------------------------------------------------------------------------

We next wanted to test the possibility that CELF2 also drives a broader program of activation-induced APA. As discussed in the introduction, widespread changes in APA have been observed upon activation of T cells and other transitions between differentiation and proliferation ([@R7]; [@R15]; [@R28]), although in most cases the mechanism(s) driving such signal-induced APA have not been fully determined. The fact that CELF2 expression increases upon activation of Jurkat T cells ([Figure 1C](#F1){ref-type="fig"}), and CELF2 regulates activation-induced APA of its own transcript, suggests that increased expression of CELF2 may be one of the drivers of activation-induced APA transcriptome-wide. Consistently, when we overlap the location of CELF2 binding in 3′ UTRs with PAS sequences used in lymphoid tissues (spleen, lymph node, and thymus from APASdb; [@R41]), we find that more than 10% of these PAS sequences have a flanking CELF2 binding site within 100 nt ([Figure 5A](#F5){ref-type="fig"}). By comparison, hnRNP L, which also binds extensively in 3′ UTRs in T cells ([@R29]), is found within 100 nt of fewer than 2% of PAS sequences ([Figure 5A](#F5){ref-type="fig"}). Mapping of the CELF2 and hnRNP L CLIP peaks around the PAS sequences identified in various lymphoid tissues further highlights the tendency of CELF2 to bind around PAS sites, with particular enrichment immediately upstream of the hexamer ([Figure 5B](#F5){ref-type="fig"}). To determine if this profile of CELF2 binding might overlap with CFI and CstF, we compared our CELF2 CLIP data with CLIP-seq data on the CFI and CstF complexes in the K562 lymphoblast cell line ([www.encodeproject.org](http://www.encodeproject.org)). We find that 6% and 10% of CELF2 binding sites directly overlap with CstF and CFI binding sites, respectively ([Figure 5C](#F5){ref-type="fig"}). Again, in contrast, only 2.5% and 1% of hnRNP L peaks overlap with CstF and CFI sites, respectively ([Figure 5D](#F5){ref-type="fig"}). The overlap of CELF2 particularly with CFI binding is also apparent in a density map of CLIP peaks around PAS sites ([Figure 5E](#F5){ref-type="fig"}).

CELF2 Regulates a Broad Program of Activation-Induced APA in Jurkat Cells {#S7}
-------------------------------------------------------------------------

To directly assess the functional role of CELF2 on APA, especially of that triggered in a signal-responsive manner, we analyzed our pre-existing RNA-seq data from Jurkat cells ([@R13]) with the DaPars algorithm ([@R39]). Comparison of the transcriptome of wild-type JSL1 cells preand post-stimulation identified 218 genes that undergo signal-responsive APA with a change of at least 20% between alternative sites ([Table S2](#SD3){ref-type="supplementary-material"}; [Figure 6A](#F6){ref-type="fig"}). Remarkably, in almost half of these genes (96 of 218) we also observe APA changes upon depletion of CELF2 as detected by DaPars analysis and validated by 3′ RACE ([Table S2](#SD3){ref-type="supplementary-material"}; [Figures 6A](#F6){ref-type="fig"}--[6E](#F6){ref-type="fig"}; [Figure S5](#SD1){ref-type="supplementary-material"}). In many of these cases, depletion of CELF2 in stimulated cells clearly induces a polyadenylation pattern similar to unstimulated wild-type cells ([Figures 6B](#F6){ref-type="fig"}--[6E](#F6){ref-type="fig"}). Moreover, consistent with the meta-gene analysis in [Figure 5](#F5){ref-type="fig"}, for many of the CELF2-dependent APA events we observe binding of CELF2 proximal to the PAS sites and overlapping binding of the CFIm and CstF complexes ([Figures 6B](#F6){ref-type="fig"}--[6E](#F6){ref-type="fig"}). These data confirm that CELF2 is a major driver of activation-induced APA, at least in the Jurkat T cells, and suggests that CELF2 generally regulates APA in a manner analogous its role as a repressor of splicing, namely, by competing with the binding of critical components of the processing machinery ([Figure 6F](#F6){ref-type="fig"}; see [Discussion](#S8){ref-type="sec"}).

The regulation of APA is predicted to affect protein expression through control of mRNA stability and/or translation. Indeed, we note that several of the genes for which we observe significant APA in Jurkat cells upon stimulation and depletion of CELF2 also exhibit large changes in mRNA abundance ([Figure 7A](#F7){ref-type="fig"}; [Table S3A](#SD4){ref-type="supplementary-material"}), although we observe no specific correlation between 3′ UTR shortening or lengthening and transcript abundance ([Table S3A](#SD4){ref-type="supplementary-material"}). We also analyzed recent mass spectrometry data from our Jurkat cells (L.M.A., B.A. Garcia, and K.W.L., unpublished data) to determine if protein expression is altered for any of the genes in which we observe CELF2 and/or stimulation-induced APA. Again, although we observe no general trend between APA and protein abundance, we do detect several instances of altered protein abundance ([Table S3](#SD4){ref-type="supplementary-material"}). For example, for SLC2A3 and LRCH4, we observe that the change in APA correlates with significant (\~11- and 5-fold, respectively) changes in protein expression ([Figure 7B](#F7){ref-type="fig"}; [Table S3](#SD4){ref-type="supplementary-material"}), while only SLC2A3 also has a significant change in mRNA abundance ([Figure 7A](#F7){ref-type="fig"}). A more modest change in protein (\~2-fold) is also observed for five additional genes for which we observe CELF2-dependent APA ([Table S3B](#SD4){ref-type="supplementary-material"}; [Figure 7B](#F7){ref-type="fig"}, note log scale). The sensitivity of this protein abundance data was confirmed by the lack of change in the abundance of hnRNP L, and marked increase in CD69 upon stimulation of Jurkat cells, consistent with previous studies ([@R29]; [@R36]). Thus, these data suggest that at least a subset of CELF2-dependent APA events may regulate translation to shape the proteome in activated cells.

We were particularly intrigued by the identification of RBFOX2 mRNA as a target of CELF2-dependent APA, as we have previously reported that CELF2 represses the expression of RBFOX2 protein to control splicing of a broad program of RBFOX2-target genes; however, the mechanism by which CELF2 regulates RBFOX2 expression was unknown ([@R13]). RBFOX2 has two alternative sites of polyadenylation, the more distal of which is only used upon depletion of CELF2 in Jurkat cells ([Figure 7C](#F7){ref-type="fig"}). To ask if CELF2-mediated repression of this distal site controls the expression of RBFOX2 protein, we transfected cells with an antisense morpholino oligo (AMO) that is complementary to this distal PAS site. As predicted, this AMO inhibits use of the distal PAS even in cells depleted of CELF2 ([Figure 7C](#F7){ref-type="fig"}, RACE). Remarkably, inhibition of the distal PAS completely blocked the increase in RBFOX2 protein that is typically induced upon depletion of CELF2 ([Figure 7C](#F7){ref-type="fig"}, western blot). Therefore, we conclude that CELF2-induced regulation of APA has a direct impact on RBFOX2 expression, and thus the subsequent gene expression profile that we have previously shown is a result of the functional antagonism between these two proteins ([@R13]).

DISCUSSION {#S8}
==========

APA is broadly observed in human transcripts and has been shown to be highly regulated in response to cell stimulation ([@R11]; [@R14]; [@R28]; [@R35]; [@R34]). Here we identify a previously unrecognized role for the RBP CELF2 in regulating APA and provide evidence that CELF2 controls an extensive program of APA transcriptome-wide. Specifically, we show that CELF2 binding overlaps and competes with polyadenylation enhancer activities located upstream and downstream of the primary PAS site ([Figure 6F](#F6){ref-type="fig"}). At a transcriptome-wide level, this competition may be most generally with CFI bound to UGUA sites upstream of the PAS sequence, given the marked peak of CELF2 binding \~100 nt before the PAS exactly overlapping the peak of CFI binding ([Figures 5B](#F5){ref-type="fig"} and [5C](#F5){ref-type="fig"}). However, in the case of regulation of its own APA, CELF2 activity is also sensitive to the presence of the enhancer element downstream of PAS2 that binds CstF ([Figure 4](#F4){ref-type="fig"}). Notably, at a transcriptome-wide level, CELF2 binding is enriched downstream of the PAS compared with the control protein hnRNP L ([Figure 5B](#F5){ref-type="fig"}). Moreover, some CstF binding is observed upstream of the PAS in addition to the dominant binding peak downstream ([Figures 5C](#F5){ref-type="fig"} and [5E](#F5){ref-type="fig"}). Previously, Shi and colleagues showed that CFI promotes recruitment of CstF as well as CPSF, concluding that the CPAFs assemble cooperatively around PAS sites ([@R42]). Taken together, these data suggest that CELF2 functions at multiple points to disrupt the efficient assembly of an active CPAF complex, including obscuring the binding site of CFI as well as CstF. Which interactions are most sensitive to CELF2 competition and most disruptive to PAS site use is likely highly dependent on the precise sequences and context of each gene.

The activity of CELF2 in regulating APA through competition with core enhancer activities is highly reminiscent of at least one mechanism by which splicing is regulated by CELF2, namely, competition with the splicing machinery at the 3′ splice site ([Figure 6F](#F6){ref-type="fig"}). [@R10] showed that CELF2 causes exon skipping by binding across the branchpoint sequence of the 3′ splice site. Such interactions block association of U2AF65 and the U2 snRNP with the intron ([@R10]; [@R12]), thereby favoring use of the downstream competing 3′ splice site. Consistently, we have observed that \~25% of exons in Jurkat cells that are skipped in a CELF2-dependent manner exhibit binding of CELF2 within the 3′ splice site region ([@R2]). Here we find that binding of CELF2 to the 3′ splice site of a terminal intron similarly blocks U2AF65 binding but in this case causes IR. IR is indeed the expected consequence of U2AF65 repression of a terminal 3′ splice site, as there is no alternative 3′ splice site downstream to allow assembly of the catalytic spliceosome complex. Importantly, we show here that although IR and APA can both occur in the same 3′ UTR, and both involve inhibition of core machinery, these regulatory processes are mechanistically uncoupled. Specifically, we find no difference in CELF2-induced APA in the presence or absence of the intron ([Figure 3B](#F3){ref-type="fig"}), and our intron reporter lacks both PAS2 and PAS3 ([Figure 2B](#F2){ref-type="fig"}). Therefore, we conclude that the CELF2 shapes 3′ UTR identity by at least two independent processes: APA and alternative splicing.

The identification of CELF2 as a regulator of polyadenylation provides an important new function to this protein. Interestingly, previous studies have determined that the close homolog CELF1 also exhibits enrichment of binding to 3′ UTRs ([@R38]). However, in these studies CELF1 was reported to function primary in cytoplasmic mRNA stability and decay ([@R24]; [@R38]). Consistently, at least in Jurkat cells, CELF1 is dominantly expressed in the cytoplasm, while CELF2 is largely nuclear ([@R20]). Moreover, in our knockdown and KO models of CELF2 we see no change in CELF1 expression ([@R23]), yet we see a functional change in APA and splicing, indicating that CELF1 cannot functionally substitute for CELF2 in these processes. Therefore, we conclude that although CELF1 and CELF2 both bind extensively to 3′ UTRs, the functional consequence of these binding events is largely distinct.

Importantly, although we demonstrate here that CELF2 regulates many instances of activation-induced APA, we assume we have underestimated the scope of CELF2 mediated regulation of APA, as DaPars analysis has been shown to miss some APA events, especially among lowly expressed genes or those that contain more than two PAS sites ([@R39]). Our focus in this study has been on the identification and mechanism of CELF2 as an APA regulatory factor; however, moving forward, it will be exciting to extend our studies here to identify the full program of CELF2 mediated APA in T cells as well as other tissues in which CELF2 is highly expressed such as muscle and neurons.

STAR★METHODS {#S9}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S10}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Kristen W. Lynch (<klync@pennmedicine.upenn.edu>). Reporter constructs generated in this study are all freely available upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S11}
--------------------------------------

To generate CELF2 knockout clones, we used CRISPR editing that targeted CELF2 in Jurkat cells. Briefly, a custom designed crRNA (AUUUUCUGUCUUCCACAGCU) was annealed to tracrRNA (Dharmacon). This annealed gRNA complex (80 μM) was then mixed 1:1 by volume with 40 μM *S. pyogenes* Cas9-NLS (University of California Berkeley QB3 Macrolab) to a final concentration of 20 μM Cas9 ribonucleotide complex (RNP). This complexed gRNA:Cas9 RNP was nucleofected into Jurkat cells with the SE. Cell Line 96-well Nucleofector Kit using a 4-D Nucleofector following the manufacturer's recommendations (Lonza). Edited cells were cultured for 2--3 days before single-cell sorted (FACS Aria) into 96-well plates to generate single-cell clones. Clones were screened by sequencing of genomic DNA and by western blot. CELF2 depletion (knock-down) or overexpression was done using previously described Jurkat cells stably expressing doxycycline inducible FLAG-tagged CELF2 cDNA or shRNA targeting CELF2 ([@R21]). All Jurkat cells were cultured in in RPMI (Corning) supplemented with 5% heat-inactivated fetal bovine serum (FBS) (GIBCO) as described previously ([@R18]). HeLa cells were cultured in DMEM (Corning) with 10% heat-inactivated FBS. For stimulations, Jurkat T cells were cultured with 20 ng/mL PMA (Sigma-Aldrich) for 48 h (RT--PCR and 30RACE), or the indicated time points for western blot analyses. Jurkat cells are male, HeLa cells are female.

METHOD DETAILS {#S12}
--------------

### Transfections {#S13}

HeLa cells were transfected with indicated plasmids containing CELF2 3′UTR constructs (4 μg total DNA) by Lipofectamine 2000 (Invitrogen) transfection reagent according to the manufacturer's instructions. Cells were harvested 24 hours post-transfection for RT-PCR, 3′RACE and western blot analyses. To alter RBFOX2 APA Jurkat cells were transfected with 10 nmol of an AMO blocking distal polyA site of RBFOX2 3′UTR (5′ GAAGCACTGTTTTTAAATAAAAGAGAGAAACACCA 3′; GeneTools) by electroporation as previously described ([@R18]; [@R27]). Cells were incubated with AMO for 16 h after transfection and then treated with doxycycline to induce depletion of CELF2 for 48 hours.

### RT-PCR {#S14}

RNA from Jurkat and HeLa cells were isolated using RNABee (Tel-Test, Inc.) according to the manufacturer's instructions. Low-cycle RT-PCR was carried out and analyzed as previously described ([@R18]; [@R27]) using sequence-specific primers for individual genes. Primer sequences used for RT-PCR experiments are provided in [Table S4](#SD1){ref-type="supplementary-material"}.

### 3′RACE {#S15}

RACE-Ready cDNA were produced and transcript 3′ ends were identified by SMARTer RACE cDNA Amplification Kit (Clontech) according to the manufacturer's instructions. RACE-Ready cDNA were analyzed on agarose gels. Gene specific forward primers used for amplification of RACE-Ready cDNA are listed in [Table S4](#SD1){ref-type="supplementary-material"}.

### Western blots {#S16}

Western blots were carried out as previously described ([@R26]). Briefly, 10 μg of total protein lysates were loaded into 10% 37.5:1 bis-acrylamide SDS-PAGE gels. Antibodies used for western blot analyses are listed in the [Key Resources Table](#T1){ref-type="table"}.

### UV crosslinking and immunoprecipitation {#S17}

*In vitro* UV crosslinking assays were performed as previously described ([@R2]). Briefly, CELF2 3′UTR constructs were *in vitro* transcribed from a T7 promoter and body-labeled with ^32^P α-UTP. Nuclear extracts from unstimulated or stimulated Jurkat cells or purified recombinant proteins were incubated with 3′UTR RNAs, UV cross-linked, RNase-digested, and resolved on an SDSPAGE. For UV crosslinking followed by immunoprecipitation, UV cross-linking reactions after RNase digestion were incubated with corresponding primary antibodies overnight at 4°C in RIPA buffer followed by incubation with protein-G Sepharose beads (GE) and elution. 200 ng of purified recombinant CELF2 protein ([@R2]) or hnRNPL protein ([@R8]) was mixed with nuclear extract from unstimulated Jurkat cells for UV crosslinking followed by immunoprecipitation in [Figure 2E](#F2){ref-type="fig"}. Amounts of purified recombinant CELF2, CFIm25, CstF64, hnRNPL and hnRNPK proteins used for *in vitro* UV crosslinking experiments are as indicated in the [Figures 4](#F4){ref-type="fig"} and [S4](#SD1){ref-type="supplementary-material"}. Sources of the recombinant proteins are listed in [Key Reources Table](#T1){ref-type="table"}. Antibodies used for immunoprecipitation are listed in [Key Resources Table](#T1){ref-type="table"}.

### Mutagenesis {#S18}

Specific protein binding sequences in CELF2 3′UTR constructs ([Figures 3D](#F3){ref-type="fig"} and [3E](#F3){ref-type="fig"}) were mutated using QuickChange Lightening Site-Directed Mutagenesis kit (Agilent Technologies) according to manufacturer's instructions. Sequence specific primers used for mutagenesis are listed in [Table S4](#SD1){ref-type="supplementary-material"}.

### LC-MS/MS analysis {#S19}

Protein sample processing for mass spectrometry (MS) was carried out as described previously (L.M.A., B.A. Garcia, and K.W.L., unpublished data). In brief, unstimulated and PMA stimulated JSL1 cells were harvested after 48 hours of treatment and lysed in a sequential, two-step manner in order to fractionate cells into cytoplasmic versus nuclear fractions. Proteins were digested with trypsin and analyzed using a Dionex UltiMate 3000 (Thermo Scientific, San Jose, CA, USA) liquid chromatography (LC) system coupled online with a Q Exactive HF-X instrument (Thermo Scientific, San Jose, CA, USA). LC was configured with a 75 μm ID × 20 cm Reprosil-Pur C~18~-AQ (3 μm; Dr. Maisch GmbH, Germany) reverse phase capillary column packed in-house. Data was analyzed by the Sequest HT search engine in Proteome Discoverer v2.3 (Thermo Scientific), using a full human proteome database with canonical protein sequences (SwissProt, release 2018_05) and a 1%false discovery rate (FDR). Cytoplasmic and nuclear samples were considered as fractions of the same cellular condition.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S20}
---------------------------------------

Statistical analysis for the quantification of differential alternative polyadenylation in [Table S2](#SD3){ref-type="supplementary-material"} was done according to the DaPars pipeline using the standard default settings ([@R39]). For the proteomic data ([Table S3](#SD4){ref-type="supplementary-material"}), significant changes were determined by performing a two-tailed homoscedastic t test between unstimulated and stimulated conditions; our significance cutoff was p value \< 0.05 (or 4.32 when--log2 transformed). For the RT-PCR analysis of intron retention in [Figures 2](#F2){ref-type="fig"} and [S2](#SD3){ref-type="supplementary-material"}, we provide standard deviation as calculated from three independent replicate experiments.

DATA AND CODE AVAILABILITY {#S21}
--------------------------

The unique proteomic data used for this study is available in the PRIDE database (PDX012556).

Supplementary Material {#SM1}
======================
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SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.celrep.2019.08.022>.

DECLARATION OF INTERESTS

The authors declare no competing interests.

![CELF2 Binds Its Own 3′ UTR and Induces Intron Retention and Alternative Polyadenylation\
(A) Transcriptome distribution of CELF2 CLIP-seq peaks (black; from [@R2]) compared with total Ref-Seq transcriptome (gray).\
(B) Schematic of CELF2 CLIP peaks mapped along the 3′ UTR of CELF2 mRNA. Light gray boxes are exons, thin and thick dark gray line and/or box are the spliced and retained intron. The relative location of two alternative PAS sites (PAS2 and PAS3) is indicated. No CLIP peaks for CELF2 are detected downstream of PAS3.\
(C) Representative detection of CELF2 protein (by western blot, top), CELF2 mRNA 3′ UTR intron retention (by RT-PCR, middle), and switch from PAS2 to PAS3 (by 3′ RACE, bottom) following stimulation of Jurkat cells with PMA for the indicated time points. HnRNPL is used as a loading control for the western blot, as this has previously been shown not to change in response to PMA ([@R29]).\
(D) Quantification of the data in (C) along with replicates (n = 3). PAS3 quantification is relative to PAS2 (i.e., PAS3/\[PAS3 + PAS2\]).\
(E) Quantification of assays such as in (C) but following induction of CELF2 protein with a doxycycline-driven CELF2 cDNA construct (n = 3). Error bars in both (D) and (E) represent SD. Representative gels for (E) are shown in [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1539604-f0001){#F1}

![CELF2 Is Necessary and Sufficient for Intron Retention by Inhibiting U2AF65 Binding\
(A) Analysis of CELF2 3′ UTR intron retention by RTPCR in parental wild-type Jurkat cells versus cells that express no detectable CELF2 protein because of CRISPR-mediated frameshift (KO). Western blot confirms lack of CELF2 protein with hnRNP L as loading control. See also [Figure S2](#SD1){ref-type="supplementary-material"}.\
(B) Analysis of intron retention in CELF2 3 ′UTR intron reporter construct that contains the first 2.5 kb of the CELF2 3′ UTR (inclusive of the whole intron and flanking sequences), upon transfection of HeLa cells with the reporter alone or together with CELF2 or GFP cDNA as indicated.\
(C) Schematic of the CELF2 3′ UTR highlighting the sequences in the 3′ splice site region of the intron and location of U2AF65 and CELF2 binding sites, as well as the results of CLIP-seq.\
(D) *In vitro* UV crosslinking of nuclear extract from unstimulated (−PMA) or stimulated (+PMA) Jurkat cells with *in vitro* transcribed, radiolabeled RNA corresponding to 120 nt encompassing the intron sequences highlighted in (C). "+IP" lanes are those in which immunoprecipitation with the indicated antibody was done after crosslinking and RNase treatment. Precipitated product is then run on the SDS-PAGE gel.\
(E) Same as (D), but all reactions are done with nuclear extract from unstimulated Jurkat cells, in the absence (−) or presence (+) of 200 ng purified recombinant CELF2 or recombinant hnRNPL. Asterisk indicates a protein that binds non-specifically to Protein-G Sepharose beads.](nihms-1539604-f0002){#F2}

![CELF2 Is Necessary and Sufficient for the Switch to PAS3 and Binds to Sequences Overlapping Enhancer Elements Required for PAS2\
(A) Analysis of CELF2 polyadenylation site use by 3′ RACE in parental wild-type Jurkat cells versus cells that express no detectable CELF2 protein because of CRISPR-mediated frameshift (KO). Western blot confirms lack of CELF2 protein with hnRNP L as loading control, as also shown in [Figure 2A](#F2){ref-type="fig"}. See also [Figure S3](#SD1){ref-type="supplementary-material"}.\
(B) Analysis of polyadenylation in CELF2 3′ UTR PAS reporter construct that contains either the entire CELF2 3′ UTR (+Intron), or just sequences after the intron (−Intron), when transfected into HeLa cells either alone or together with CELF2 or GFP cDNA as indicated.\
(C) Schematic of the CELF2 3′ UTR highlighting the sequences surrounding the PAS2 and PAS3 sites, highlighting the PAS hexamer sequence (orange), location of the upstream enhancer (UE; box) and downstream enhancer (DE; underline) sequences, and location of CELF2 binding sites (blue).](nihms-1539604-f0003){#F3}

![CELF2 Competes with CFIm25 and CstF64 to Regulate APA of Its Own 3′ UTR\
(A and B) *In vitro* UV crosslinking analysis of indicated amount of recombinant CstF64 (A) or CFIm25 (B) protein bound to radiolabeled PAS2 oligonucleotide in the absence or presence of increasing amounts of recombinant CELF2 (left) or hnRNPL (right). hnRNPL protein crosslinked to M1 oligonucleotide ([@R33]) is shown as a positive control for hnRNPL binding to RNA. The lane with hnRNP L alone was run on a different gel. (C) Left, schematic of reporter constructs and right, 3ʹ RACE analysis of mutant constructs upon transfection in HeLa cells with (+) or without (−) cotransfected CELF2 cDNA. Asterisk marks the product resulting from use of SV40 PAS. Red boxes indicate location of mutations that disrupt binding of CstF64, CFIm25, and CELF2, as indicated in the text. swPAS3 lacks all sequences around the native PAS3 (shown as a dark gray box), such that the vector-encoded non-PMA responsive SV40 polyA is the only other PAS present.\
See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1539604-f0004){#F4}

![CELF2 Binding Overlaps Extensively with APA Enhancer Activities Transcriptome-wide\
(A) Number of PAS sites identified in at least two lymphoid tissues (total), from APASdb ([@R41]), that overlap with CELF2 or hnRNP L CLIP-peaks from Jurkat cells ([@R2]; [@R29]).\
(B) Mapping of CLIP-peak density across a 1 kb interval before and after PAS sites identified in lymphoid tissues. Color intensity indicates confidence of PAS site, on the basis of identification in one (light), two (medium), or three (dark) of the lymphoid tissues.\
(C) Number of CFI (top) or CstF (bottom) CLIP-peaks from K562 cells ([www.encodeproject.org](http://www.encodeproject.org)) that overlap with CELF2 CLIP-peaks from Jurkat cells ([@R2]; [@R29]). Total number of CELF2 peaks and total number of overlapped peaks are given.\
(D) Same as (C) but with hnRNP L CLIP-peaks from Jurkat cells ([@R2]; [@R29]).\
(E) Same as in (C) but mapping of the CFI and CstF Encode data as well as the CELF2 and hnRNP L data around the highest confidence PAS sites.](nihms-1539604-f0005){#F5}

![CELF2 Regulates a Broad Program of Activation-Induced APA in Jurkat Cells\
(A) Number of CELF2-regulated APA events that overlap with total activation-induced APA events, as detected by DaPars analysis ([@R39]) of RNA-seq data from Jurkat cells.\
(B--E) 3′ RACE analysis of APA of the genes LRCH4 (B), RCCD1 (C), PNPO (D), and TNKS (E) in wild-type (WT) or CELF2-deficient (KD) cells before (−) or after (+) stimulation with PMA. For each panel, the gene name, 3′ UTR schematic, and RNA-seq tracks are shown from the indicated cell conditions. Proximal (P) and distal\
(D) PAS sites are indicated. CELF2 CLIP peaks from stimulated Jurkat cells (bottom bright red tracks), CFIm68 CLIP peaks from K562 cells (bottom yellow tracks), and CstF64 CLIP peaks from HepG2 cells (bottom gray tracks) are also shown. See [Figure S5](#SD1){ref-type="supplementary-material"} for more examples.\
(F) Model showing CELF2 regulation of 3′ UTR IR and APA by competition with core processing machinery. Top: CELF2 promotes 3′ UTR IR by inhibiting U2AF65 binding to 3′ splice site. Bottom: CELF2 regulates APA by competing with core enhancer factors CFI and CstF upstream and downstream of PAS, respectively.](nihms-1539604-f0006){#F6}

![Functional Impacts of CELF2-Mediated APA\
(A) A scatterplot of stimulation-induced change in steady-state transcript level (log~2~\[FC\]) versus APA shifts (percentage distal polyA site usage index \[PDUI\]) for CELF2 target genes. Genes that also exhibit changes in their encoded protein (see B) are highlighted in red and labeled.\
(B) Abundance of proteins encoded by genes with CELF2 and/or activation-dependent APA (plus proteins known to change \[CD69\] or not \[hnRNP L\]) upon stimulation. Relative abundance is calculated from shotgun proteomics of Jurkat cells before and after stimulation, as described in the [STAR Methods](#S9){ref-type="sec"}. Error bars represent SE from at least two independent experiments.\
(C) 3′ RACE analysis of APA of RBFOX2 in wild-type (WT) or CELF2-deficient (KD) cells without (−) or with (+) transfection of AMO targeting RBFOX2 distal site. 3′ UTR schematic and RNA-seq tracks are shown from the indicated cell conditions. Proximal(P) and distal (D) PAS sites are indicated. CELF2 CLIP peaks from stimulated Jurkat cells (bottom bright red tracks), CFIm68 CLIP peaks from K562 cells (bottom yellow tracks), and CstF64 CLIP peaks from HepG2 cells (bottom gray tracks) are also shown. Western blots show that inhibition of the distal PAS completely blocked the increase in RBFOX2 protein that is typically induced upon depletion of CELF2. hnRNPL is used as a loading control. AMO, antisense morpholino oligo.](nihms-1539604-f0007){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                    SOURCE                                            IDENTIFIER
  ------------------------------------------------------ ------------------------------------------------- ---------------------------------------------------------
  Antibodies                                                                                               
  CELF2                                                  University of Florida ICBR                        HL1889; RRID:AB_1078584
  U2AF65                                                 Sigma                                             U4758; RRID:AB_262122
  hnRNPL                                                 Abcam                                             Ab6106; RRID:AB_305294
  FLAG-tag                                               Cell Signaling Technology                         2368S; RRID:AB_10707327
  RBFOX2                                                 Bethyl                                            (A300--864A); RRID: AB_609476
  Chemicals, Peptides, and Recombinant Proteins                                                            
  RPMI 1640                                              Corning                                           10-040-CV
  DMEM                                                   Corning                                           10-013-CV
  FBS                                                    GIBCO                                             16000-044
  Lipofectamine 2000 reagent                             Invitrogen                                        52887
  Protein G Sepharose beads                              GE Healthcare                                     17-0618-01
  Recombinant CFIm25                                     Abcam                                             ab104669
  Recombinant CstF64                                     Origene                                           TP304450
  Recombinant CELF2                                      Dr. Kristen W. Lynch                              [@R2]
  Recombinant hnRNPL                                     Dr. Kristen W. Lynch                              [@R8]
  Recombinant hnRNPK                                     Dr. Kristen W. Lynch                              [@R33]
  *S. pyogenes* Cas9-NLS                                 UC Berkeley QB3 Macrolab                          N/A
  Critical Commercial Assays                                                                               
  SMARTer RACE cDNA Amplification Kit                    Clontech                                          634858
  QuickChange Lightening Site-Directed Mutagenesis kit   Agilent Technologies                              210518--5
  Nucleofector Kit using a 4-D Nucleofector              Lonza                                             V4XC-2012
  Deposited Data                                                                                           
  Proteomic data                                         Dr. Benjamin A. Garcia and Dr. Kristen W. Lynch   PRIDE database: (PDX012556)
  Experimental Models: Cell Lines                                                                          
  Human: JSL1 Jurkat T cells                             Dr. Kristen W. Lynch                              [@R18]
  Human: HeLa cells                                      ATCC                                              N/A
  Human: CELF2 KO Jurkat T cells                         This study                                        N/A
  Oligonucleotides                                                                                         
  Primers for RTPCR and 3'RACE                           This study                                        See [Table S4](#SD1){ref-type="supplementary-material"}
  Primers for 3′UTR mutagenesis                          This study                                        See [Table S4](#SD1){ref-type="supplementary-material"}
  Primers for UV crosslinking                            This study                                        See [Table S4](#SD1){ref-type="supplementary-material"}
  Recombinant DNA                                                                                          
  Plasmid: CELF2 3′UTR intron reporter                   This study                                        N/A
  Plasmid: CELF2 3′UTR PAS (+Intron) reporter            This study                                        N/A
  Plasmid: CELF2 3′UTR PAS (−Intron) reporter            This study                                        N/A
  Plasmid: mUE-C2                                        This study                                        N/A
  Plasmid: mDE-C2                                        This study                                        N/A
  Plasmid: mU/D-C2                                       This study                                        N/A
  Plasmid: mUE                                           This study                                        N/A
  Plasmid: mDE                                           This study                                        N/A
  Plasmid: mU/D                                          This study                                        N/A
  Plasmid: sw-PAS3                                       This study                                        N/A
  Software and Algorithms                                                                                  
  DaPARs analysis                                        [@R39]                                            <https://code.google.com/p/dapars/>
  MAJIQ algorithm                                        [@R37]                                            <https://majiq.biociphers.org>

###### Highlights

-   The RNA-binding protein CELF2 competes for binding with 3′ end processing factors

-   CELF2 regulates a broad program of cellular alternative polyadenylation (APA)

-   Increased CELF2 protein upon cell stimulation drives stimulation-induced APA

-   CELF2 regulates RBFOX2 expression by limiting use of a distal polyadenylation site

[^1]: AUTHOR CONTRIBUTIONS

    R.C. performed the majority of the experimental work, with assistance from M.J.M. W.S.Z., A.J.L., and K.M.A. generated the CRISPR KO clone. M.R.G. carried out the CLIP and DaPars analysis in [Figures 5](#F5){ref-type="fig"} and [6A](#F6){ref-type="fig"}. L.M.A. performed the proteomic analysis in [Figure 7](#F7){ref-type="fig"}. R.C. and K.W.L. directed the project and wrote the manuscript.
